Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq analysis for IRF4-driven zebrafish tumors after JQ1 treatment

ABSTRACT: RNA-seq analysis was performed using tumor cells driven by IRF4 to analyze gene expression changes after JQ1 treatment

ORGANISM(S): Danio rerio

PROVIDER: GSE184946 | GEO | 2022/03/14

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

RNA-seq analysis for IRF4-driven zebrafish tumors after JQ1 treatment

Project description:RNA-seq analysis for IRF4-driven zebrafish tumors after JQ1 treatment

| PRJNA767083 | ENA

Zebrafish tumors driven by overexpression of human IRF4

Project description:Zebrafish tumors driven by overexpression of human IRF4

| PRJNA701471 | ENA

RNA-seq analysis for zebrafish tumors driven by overexpression of human IRF4

Project description:RNA-seq analysis was performed using zebrafish primary tumors and control thymus to analyze gene expression changes after IRF4 overexpression.

2022-03-14 | GSE139226 | GEO

H3K27ac ChIP-seq analysis for zebrafish normal thymus and tumors driven by overexpression of human IRF4

Project description:H3K27ac ChIP-seq analysis was performed using zebrafish normal thymus and primary tumors to analyze potential regulatory elements activated by IRF4 overexpression.

2022-03-14 | GSE166644 | GEO

Single cell RNA-seq analysis for normal lymphocytes and IRF4-driven zebrafish tumors

Project description:Single cell RNA-seq analysis was carried out for 1 normal sample from a control zebrafish line (lck-mCherry) and 5 non-tumor and 14 tumor samples from the IRF4 transgenic line (lck-IRF4). Tumor cells were harvested from the animals with or without heterozygous p53 mutation at different time points of tumor development.

2022-03-14 | GSE166646 | GEO

RNA-seq analysis for zebrafish tumors driven by overexpression of human IRF4

Project description:RNA-seq analysis for zebrafish tumors driven by overexpression of human IRF4

| PRJNA578840 | ENA

Single cell RNA-seq analysis for normal lymphocytes and IRF4-driven zebrafish tumors

Project description:Single cell RNA-seq analysis for normal lymphocytes and IRF4-driven zebrafish tumors

| PRJNA701473 | ENA

H3K27ac ChIP-seq analysis for zebrafish normal thymus and tumors driven by overexpression of human IRF4

Project description:H3K27ac ChIP-seq analysis for zebrafish normal thymus and tumors driven by overexpression of human IRF4

| PRJNA701468 | ENA

Zebrafish tumors driven by overexpression of human IRF4

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-03-14 | GSE166650 | GEO

IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma

Project description:Multiple myeloma (MM) is an incurable malignancy of plasma cells that exploits transcriptional networks driven by IRF4. To discover unique molecular vulnerabilities in MM centered on IRF4, we employ a multi-omics approach integrating functional genomics screening, spatial proteomics, and global chromatin mapping. We find that ARID1A, a member of the SWI/SNF chromatin remodeling complex, is both required for IRF4 expression and functionally associated with IRF4 protein on chromatin. Deletion of Arid1a in activated murine B cells thwarts subsequent plasma cell differentiation by disrupting IRF4-dependent transcriptional networks, therefore defining ARID1A as a novel plasma cell vulnerability. Targeting ARID1A-dependent SWI/SNF activity via SMARCA2/4 inhibition induces a rapid loss of IRF4-target gene expression and quenches global amplification of oncogenic gene expression driven by MYC, resulting in profound toxicity to MM cells. Notably, MM patients with aggressive disease have markers of SWI/SNF activity, and SMARCA2/4 inhibitors retain their activity in immunomodulatory drug (IMiD)-resistant MM cells. To fully harness the potential of these drugs, we use combinatorial drug screens to uncover profound synergistic toxicity between SMARCA2/4 and MEK inhibitors. Thus, targeting SWI/SNF activity potently represses an IRF4-MYC feed forward loop and provides a feasible path to effectively treat this incurable disease.

2024-01-11 | MSV000093842 | MassIVE

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data